Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation
Celltrion Group today announced that the Korean Ministry of Food and Drug Safety (MFDS) granted a Conditional Marketing Authorisation (CMA) for the emergency use of Regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. The CMA allows for emergency use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19.
The CMA is based on Part 1 of the Phase II/III trial which showed;
- Patients treated with CT-P59 reporting a significantly reduced risk of COVID-19 related hospitalization and oxygenation up to Day 28
- Progression rates to severe COVID-19 were reduced by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over
- A significantly shortened time to clinical recovery in CT-P59 treated patients (40 mg/kg) ranging from 3.4 to 6.4 days quicker compared with placebo.
“With the pandemic still raging in Korea, we believe today’s Conditional Marketing Authorisation of Regdanvimab marks an important milestone in the fight against COVID-19” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Patients with COVID-19 in Korea now have access to a therapy according to the authorised indications early in the course of their infection. We remain committed to closely working with the regulatory agencies worldwide including the U.S. FDA and the European Medicines Agency (EMA) to ensure that patients around the world have access to safe and effective treatment against COVID-19 as in the case of Korea.”
A global Phase III clinical trial is currently recruiting and expected to enrol 1,172 patients with mild-to-moderate symptoms of COVID-19 in more than 10 global sites to evaluate efficacy and safety results of CT-P59. Celltrion is set to demonstrate clinical efficacy against COVID-19 in both UK and South African variants and the results to be expected in the coming days.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.
About CT-P59 (Regdanvimab)
CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. The mutated G-variant strain (D614G variant) was later identified and confirmed to be inactivated by CT-P59. In pre-clinical data the treatment candidate demonstrated a 100-fold reduction in viral load of SARS-CoV-2, as well as a reduction in lung inflammation. Results from the global Phase I clinical trial of CT-P59 demonstrated promising safety, tolerability, antiviral effect and efficacy profile in patients with mild symptoms of COVID-19.1
FORWARD LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
1 Celltrion Data on file
For further information please contact:
+44 (0) 7751 116252
+44 (0) 7984 550312
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seglan Payments Solution Provider Turns to Verimatrix for Efficient, Time-Tested Security24.2.2021 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Seglan, an existing Verimatrix Code Protection customer and leading provider of secure payment solutions, recently selected the Verimatrix Mobile Payments technology to provide global banks and processors with time-trusted security. Seglan previously developed their own mobile payment Software Developer Kit (SDK) for implementation across its customer base. It’s now in the process of deploying Verimatrix’s mobile payments SDK that offers existing certifications for streamlining Seglan’s go-to-market capabilities aimed at some of the largest financial institutions in Europe and South America. The Verimatrix security tool will continue to be used for Seglan’s 3DSecure SDKs (certification included) while also aiming to provide their customers a full HCE and 3DSecure solution all contained within a single server. “Having successfully relied upon Ve
EnTrust Global’s Julian Proctor to Present at Economist’s World Ocean Summit24.2.2021 17:02:00 CET | Press release
Julian Proctor, Portfolio Manager of EnTrust Global’s Blue Ocean 4Impact Fund (“BO 4Impact”), will join Elisabeth Munck af Rosenschöld, Head of Supply Chain and Sustainability at IKEA, Sadan Kaptanoglu, President of BIMCO, Jeremy Nixon, Chief Executive of Ocean Network Express Co., and Craig Jasienski, Group Chief Executive at Wallenius Wilhelmsen at The Economist’ World Ocean Summit panel entitled “Shipping: Collaborating across industry and supply chains to reduce emissions.” Blue Ocean 4Impact is part of EnTrust Global’s $2+ billion maritime investment platform and is launching one of the first companies that will own and lease environmentally-advanced vessels and other marine infrastructure assets to large corporate operators and end-users, in order to help reduce carbon emissions and other pollution generated by the ocean economy. The Summit is the pre-eminent global event bringing together the widest cross-section of ocean stakeholders each year, from business to government to ci
New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection24.2.2021 17:00:00 CET | Press release
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology. The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes. The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the pre
Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management24.2.2021 16:22:00 CET | Press release
Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses. “After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Ja
Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion24.2.2021 16:00:00 CET | Press release
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/ VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire) T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients. Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorpo
KA Imaging to Present Poster on Unprecedented Lateral Dual-Energy X-ray Views at ECR 202124.2.2021 15:17:00 CET | Press release
KA Imaging, a company that develops innovative X-ray imaging solutions, announced that a poster reporting on results from a study examining the feasibility of lateral chest dual-energy subtraction radiography using a stacked single-exposure multi-layer x-ray detectorwill be presented by Sebastian Maurino, a medical physicist at KA Imaging, at this year’s European Congress of Radiology (ECR). As highlighted in the poster, KA Imaging’s novel approach allows radiologists to take full advantage of lateral dual-energy images by obtaining both conventional and dual-energy subtraction lateral images simultaneously, thereby making it considerably easier to differentiate between materials behind the heart. Quoting directly from the poster, “The DE lateral image also visualizes calcified joints and masses behind the heart that are not visible in the [Posterior-Anterior (PA)] image. Multi-layer detectors were shown to provide DE PA and lateral images of the chest at conventional patient dose leve
OAG and IATA Strengthen Data Partnership to Combat Market and Schedule Volatility24.2.2021 15:00:00 CET | Press release
OAG, the world’s leading provider of travel data and insight has agreed a partnership with International Air Transport Association (IATA), to provide schedule and reference data via its new cloud platform. As part of the strengthened partnership between the two aviation leaders, OAG will also provide IATA with a customized version of its market-leading Analyzer tool which will be offered as part of a bundle alongside Airport IS and other existing tools in the future. Built on the Snowflake cloud platform, the supply of reference and schedules data provides customers with the richest and freshest version of schedules data available in the market. “COVID-19’s ongoing impact on traffic volatility has made it critical to power our products with the most up-to-date data available,” said Charles de Gheldere, Director Aviation Data at IATA. “Our strengthened partnership with OAG supplies our airport customers with fresh and accurate data and a highly-innovative, modern and flexible cloud-base